NCT01609959

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Nara Medical University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare blood pressure lowering effect of azilsartan with that of valsartan in Japanese patients with hypertension who have already taken normal-dose angiotensin II receptor blockers.

Detailed description

Hypertension plays a major role in the development of cardiovascular disease. Several guidelines require strict control of blood pressure for preventing cardiovascular events; however, the control is often poor. A new angiotensin II receptor blocker (ARB), azilsartan, is the first drug which is superior to other ARBs in blood pressure lowering in phase III clinical trials in Japan. We try to evaluate effect of azilsartan on blood pressure lowering in Japanese patients with hypertension who have already taken normal-dose ARBs, and to compare it with that of valsartan.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Azilsartan	Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
DRUG	Valsartan	Valsartan 160 mg per day

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-09-01
• Completion: 2013-10-01
• First posted: 2012-06-01
• Last updated: 2013-10-30

Locations

1 site across 1 country: Japan